In the current study, we targeted hepatic Apoc3 expression with liver-specific ASOs and analyzed its effect on atherosclerosis development and progression dependent or independent of its triglyceride-lowering properties using mouse models (Figure 1, A–C) (11, 17). Here, APOC3 is linked to atherosclerosis.